Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP102 in Recurrent and Refractory Glioblastoma
NCT04385173Phase 1Completed
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2022
- Primary completion
- Sep 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab in glioblastoma (GBM), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Incidence and type of adverse events at 12 weeks, Maximum tolerated dose at 12 weeks and 2 more. Started Dec 2022; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04385173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385173.